Kamada (KMDA) Research & Development (2012 - 2026)
Kamada (KMDA) posted Research & Development of $2.2 million for Q1 2026, down 24.64% on a QoQ basis from $2.9 million in Q4 2025, and down 48.63% year-over-year from $4.2 million in Q1 2025.
Kamada (KMDA) Research & Development (2012 - 2026) Analysis & Trends
Kamada's Research & Development history runs 15 years deep, the most recent figure standing at $2.2 million for Q1 2026.
- Quarterly Research & Development fell 48.63% year-over-year to $2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.7 million (down 25.38% YoY) and the FY2025 annual result came in at $13.0 million, down 14.42% from the prior year.
- Research & Development was $2.2 million for Q1 2026 at Kamada, down from $2.9 million in the prior quarter.
- Across five years, Research & Development topped out at $4.4 million in Q1 2022 and bottomed at $3118.0 in Q3 2022.
- A 5-year average of $2.5 million and a median of $2.9 million in 2025 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2023 — Research & Development tumbled 99.93% — and 2024, when it surged 132830.98%.
- Kamada's Research & Development stood at $3.0 million in 2022, then increased by 8.29% to $3.2 million in 2023, then decreased by 17.47% to $2.7 million in 2024, then rose by 8.27% to $2.9 million in 2025, then slipped by 24.64% to $2.2 million in 2026.
- Business Quant data shows KMDA's Research & Development at $2.2 million in Q1 2026, $2.9 million in Q4 2025, and $2.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 696.00 Mn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 180.00 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | 7.37 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 138.20 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 248.60 Mn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 296.20 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 97.00 Mn |
| 10 | Kamada | 405.83 Mn | 332.68 Mn | 19.12 Mn | 2.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.18 Mn |
| Dec 31, 2025 | 2.89 Mn |
| Sep 30, 2025 | 2.64 Mn |
| Jun 30, 2025 | 3,219.00 |
| Mar 31, 2025 | 4.25 Mn |
| Dec 31, 2024 | 2.67 Mn |
| Sep 30, 2024 | 3.41 Mn |
| Jun 30, 2024 | 4,803.00 |
| Mar 31, 2024 | 4.30 Mn |
| Dec 31, 2023 | 3.24 Mn |
| Sep 30, 2023 | 3.18 Mn |
| Jun 30, 2023 | 4.28 Mn |
| Mar 31, 2023 | 3,231.00 |
| Dec 31, 2022 | 2.99 Mn |
| Sep 30, 2022 | 3,118.00 |
| Jun 30, 2022 | 2.64 Mn |
| Mar 31, 2022 | 4.42 Mn |
| Dec 31, 2021 | 3.45 Mn |
| Sep 30, 2021 | 2.55 Mn |
| Jun 30, 2021 | 2.74 Mn |